A Phase 4 interventional study of Alendronate 70mg weekly in Osteoporosis in Post-menopausal Women, sponsored by Odense University Hospital. Recruiting at 8 sites in Denmark. Open to female participants. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Odense University Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing alendronate in Osteoporosis — 2 open to participants now, 4 under way, none of them phase 3. Alendronate · Osteoporosis.
Among the 51 studies testing alendronate in Osteoporosis, this one has the largest planned enrollment, is the only one that started in 2025, is one of 17 in phase 4, and was the 51st registered.
1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.
Browse Osteoporosis studies →2 of the 51 studies testing alendronate in Osteoporosis are open now, in 2 countries. Recruiting first, the newest first:
Paul F Netzel · Sites in United States
Ages 45+ · Women only
By country, each count listing its studies:
Alendronate: first FDA approval 1995 (FOSAMAX), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 16 · Phase 3 15 · Phase 4 17
First in 1997; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,400 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 60 across the 51 interventional studies. Of the 42 that completed or were terminated, 18 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 51 have an industry lead sponsor. The 10 most frequent:
Odense University Hospital is the lead sponsor of 480 studies on the registry; 111 are open to participants now.
Odense University Hospital has 9 studies filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
1 of the studies testing alendronate in Osteoporosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05151484Madhumathi RaoNovel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 51 studies testing alendronate in Osteoporosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to study the effects of discontinuation of Alendronate treatment for three years. The participants are postmenopausal women with osteoporosis, who have had a treatment period without fractures. The study will answer:
Researchers will compare the outcomes of discontinuation of Alendronate with continuing treatment. Participants will be randomly assigned to a group.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Discontinuation of Alendronate treatment
Drug: Alendronate 70mg weekly
The control group will continue Alendronate treatment, but shift to project-sponsored product (70 mg Alendronate weekly)
The intervention is discontinuation of Alendronate
Fragility fractures
Incidence of fragility fractures during the study period
Time frame: From enrollment to the end of the 3 year study period.
Changes in bone mineral density (BMD)
Changes in lumbar spine and total hip BMD measured by dual energy X-ray arbsorptiometry. The three follow-up scans will be analyzed by a technician blinded to participant allocation, ie this person will not meet the patient and the patient will not be able see the results of the scans until the final study visit.
Time frame: Baseline, 12, 24 and 36 months
Bone turn over marker (CTX)
Fasting blood samples will be performed during the study period to analyze changes in carboxy-terminal collagen crosslinks (CTX).
Time frame: Blood samples are performed at baseline, 6, 12, 18, 24, and 36 months.
Bone turn over marker (P1NP)
Fasting blood samples will be performed during the study period to analyze changes in procollagen type I N-terminal propeptide (PINP).
Time frame: Blood samples are performed at baseline, 6, 12, 18, 24, and 36 months.
Restart Criteria
The proportion of participants meeting restart criteria during the study period. Restart criteria is defined as: Participants experiencing boneloss exceeding 10% from baseline in any region, one clinical vertebral fracture, two low energy fractures (including morphometric vertebral fracture but excluding fractures of scull, fingers or toes) are withdrawn from the study and offered treatment with alendronate or zoledronic acid after new diagnostic work-up.
Time frame: From enrollment to the end of the study period at 3 years
Adverse Events
At baseline a thoroughly physical examination of the participants and questioning concerning any conditions or diseases will take place. This way the investigators will be able to evaluate possible changes throughout the study. Patients will be interviewed about the occurrence of AEs at each visit from the first trial related activity after the subject has signed the informed consent. Subjects that experience adverse events or develop a disease during the trial period will be managed until the condition is cured or stationary. If this is not the case at the end of the study, subjects will be referred to a relevant physician, e.g. the general practitioner or a specialist, to be followed up.
Time frame: From enrollment to the end of the 3 year study period.
Osteoclastassay
Osteoclasts differentiation, formation, activity and response to Alendronate in cultures derived from peripheal blood at baseline from a subgroup of 35 from each arm (70 participants in total).
Time frame: Baseline
Molecular bone histology
Iliac crest bone biopsy specimens will be obtained to evaluate the effect of discontinuation of alendronate on cortical and trabecular bone resorption and formation by histomorphometry. These results will be compared with results of bone turnover markers. Biopsies will be obtained of maximum 35 from each treatment group at 12 and 36 months (in totalt 140 participants).
Time frame: 12 and 36 months
Epigenetic analysis
Epigenetic analysis of peripheal blood with focus on the degree of methylation.
Time frame: Baseline
Body composition
A subgroup of maximum 500 participants will be asked to participate in DXA whole body to assess lean mass and will be reported in grams. Scans will be performed using the same scanner throughout the study, and scans will be analysed by personnel blinded to group allocation.
Time frame: Baseline, 12, 24, and 36 months.
Physical activity, accelometry
A subgroup of maximum 500 will be asked to wear an accelerometer. Wireless accelerometers will be used to assess intensity, duration, and patterns of physical activity, and sedentary behavior. Data will be continuously collected in a raw format at 50 Hz over a period of seven days.
Time frame: Baseline and 12 months
Quality of life - Short Form Survey (SF-36)
SF-36 is a well-validated self-reported questionnaire that measures health-related quality of life. The questionnaire will be applied in Danish using version 1.1 and each item is scored on a scale from 0 to 100, where a high score indicates a more favorable health state.
Time frame: Baseline, at 12, 24 and 36 months.
Physical activity, IPAQ
A subgroup of maximum 500 will be asked to complete a validated Danish short form of the International Physical Activity Questionnaire (IPAQ). IPAQ is reported as a score of MET-min per week. More MET-min indicates more physical activity.
Time frame: Baseline, at 12, 24 and 36 months.
Lower extremity muscle strength
Maximal muscle strength of lower extremity strength will be assessed in 130 participants with an isokinetic dynamometer (System 4, Biodex Medical System Inc, New York, USA). Strength will be reported as Nm.
Time frame: Baseline, at 12, 24, and 36 months
Physical function
Short physical performance battery (SPPB) will be applied to a subgroup of 130 participants and reported on a scale from 0-12.
Time frame: Baseline, at 12, 24, and 36 months
Grip strength
Hand grip strength of 130 participants will be measured using a handheld dynamometer (Jamar Plus, Patterson Medical, Warrenville, IL, US). Strength will be reported as kg.
Time frame: Baseline, at 12, 24, and 36 months
Plan to share: Undecided — Individual anonymized data will be accessible upon reasonable request.
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Mar 2029, 48 months after the start.
Of 55 non-industry phase 4 interventional studies under Osteoporosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 71. This study's planned 48 months is close to that.
Counting every sponsor, half of 65 studies reached it within 46 months; a quarter within 29 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alendronate